Construction of recombinant mimotopes for induction of neutralizing antibodies against HIV-1 gp120 glycoprotein using high-affinity binders approach
Public support
Provider
Ministry of Health
Programme
Programme to support medical applied research in 2015 to 2022
Call for proposals
Zdravotnický AV 1 (SMZ0201501)
Main participants
Univerzita Palackého v Olomouci / Lékařská fakulta
Contest type
VS - Public tender
Contract ID
15-32198A
Alternative language
Project name in Czech
Příprava rekombinantních mimotopů indukujících neutralizační protilátky proti HIV-1 gp120 glykoproteinu pomocí technologie vysokoafinitních ligandů
Annotation in Czech
Vývoj vakcíny proti HIV-1 infekci je brzděn enormní variabilitou obalového glykoproteinu (Env), cíle neutralizačních protilátek. Identifikace sady monoklonálních protilátek neutralizujících široké spektrum variant HIV-1 (bn-mAb), reagujících s Env glykany, jako součástí jejich epitopu, nabízí novou cestu vývoje vakcíny. Jelikož kompozitní epitopy obsahující glykany jsou méně efektivní imunogeny než proteinové epitopy navrhujeme vyvinout sadu peptidů napodobujících epitopy rozlišované výše popsanými bn-mAb pomocí metody vysoce afinitních ligandů (binderů) vyvinutých spolunavrhovatelem projektu. Bindery budou selektovány na základě jejich specifické vazby na jednotlivé bn-mAb, budou fúzovány s albuminem a kotvami a ve formě proteoliposomů nebo DNA vakcín užity k imunizaci experimentálních zvířat. Poté bude charakterizována specificita, afinita a neutralizační aktivita sérových protilátek. Přístup skýtá možnost identifikovat kandidátní antigen pro vakcínu proti HIV-1 a představuje platformu pro vývoj vakcín napodobujících glykanové epitopy navozujících dobrou imunologickou paměť.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
EC - Immunology
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
—
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30102 - Immunology<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
The main aim of the project has set several successive goals that eventually cluster together and lead to the development of a vaccine against HIV1. Modern methods of reverse vaccination were used is the project, the selection of immunogenic antigens was performed by the method of molecular fingerprinting of neutralizing antibodies that proved to be successful. Selected high affinity antigens then formed the basis for a vaccine that was successfully tested in an animal models. In a view of a potential adaptation of the vaccine to human practice, the possible sublingual application on the mouse model was also tested during the project. Tested vaccines resulted in the generation of neutralizing antibodies against HIV1. Therefore, the project fulfilled its goals, the results of successive steps were summarized in 4 high impact publications, the key fifth publication is in the review process. Overall, the project fulfilled the task with excellent results, laying the foundation for further
Solution timeline
Realization period - beginning
May 1, 2015
Realization period - end
Dec 31, 2018
Project status
U - Finished project
Latest support payment
Jun 28, 2018
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP19-MZ0-NV-U/02:1
Data delivery date
Sep 16, 2019
Finance
Total approved costs
6,200 thou. CZK
Public financial support
6,200 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK